Valuation: Orgenesis Inc.

Market Cap 10L 9L 8L 7L 13.9L 9.41Cr 14.17L 95.16L 37.32L 4.62Cr 36.91L 36.1L 16Cr P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 1.92Cr 1.68Cr 1.56Cr 1.43Cr 2.71Cr 183.42Cr 2.76Cr 19Cr 7.28Cr 90Cr 7.2Cr 7.04Cr 311.07Cr EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
1 day-99.73%
1 week-99.75%
Current month-99.75%
1 month-99.78%
3 months-99.38%
6 months-99.33%
Current year-99.33%
1 week 0
Extreme 0.001
0.45
1 month 0
Extreme 0.001
0.52
Current year 0
Extreme 0.001
0.84
1 year 0
Extreme 0.0001
1.3
3 years 0
Extreme 0.0001
13.1
5 years 0
Extreme 0.0001
54.9
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 02/02/2012
Chief Executive Officer 57 24/12/2013
Director of Finance/CFO 51 10/03/2026
Director TitleAgeSince
Chairman 57 14/08/2014
Director/Board Member 55 17/04/2012
Director/Board Member 64 08/07/2024
Date Insider Type Main position Quantity % Market Cap.
05/25/05Other 12,00,000 23.2142%
12/24/12Free

Director

1,750 0.0339%
12/24/12Free

Director

1,875 0.0363%
Change 5-day change 1-year change 3-year change Capi.($)
-99.73%-99.75%-99.92%-99.99% 36.45L
-1.32%-3.17%-29.86%-14.05% 16TCr
-0.05%+0.96%-6.54%-4.76% 11TCr
+0.71%+2.06%+2.57%+59.30% 5.9TCr
+2.02%-1.74%+42.83%+58.90% 5.17TCr
+1.20%-1.07%-13.11%-40.81% 4.19TCr
-0.91%-5.01% - - 3.47TCr
+1.49%+4.90%-11.02%-43.33% 2.89TCr
+1.62%+0.36%+59.89%-6.44% 2.5TCr
-0.15%+1.13%-4.47%-5.70% 2.11TCr
Average -9.50%-1.00%-6.63%-10.77% 5.33TCr
Weighted average by Cap. +0.07%-0.95%-5.39%+0.99%

Financials

2023 2024
Net sales 5L 5L 4L 4L 7L 5.07Cr 8L 51.32L 20.13L 2.49Cr 19.9L 19.47L 8.6Cr 10.35L 9L 8L 8L 14.63L 9.91Cr 14.92L 1Cr 39.3L 4.86Cr 38.87L 38.02L 17Cr
Net income -5.54Cr -4.86Cr -4.5Cr -4.14Cr -7.83Cr -529.87Cr -7.98Cr -54Cr -21Cr -260.21Cr -21Cr -20Cr -898.63Cr -4.82Cr -4.22Cr -3.91Cr -3.6Cr -6.81Cr -461Cr -6.94Cr -47Cr -18Cr -226.39Cr -18Cr -18Cr -781.82Cr
Net Debt 2.18Cr 1.91Cr 1.77Cr 1.63Cr 3.08Cr 208.5Cr 3.14Cr 21Cr 8.27Cr 102.39Cr 8.18Cr 8Cr 353.6Cr 1.82Cr 1.59Cr 1.48Cr 1.36Cr 2.57Cr 174.01Cr 2.62Cr 18Cr 6.9Cr 85Cr 6.83Cr 6.68Cr 295.12Cr
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
13/26/13 $0.001000 -99.73% 1,232
10/26/10 $0.3720 +132.50% 213
09/26/09 $0.1600 -60.00% 121
  1. Stock Market
  2. Stocks
  3. ORGS Stock